Abstract | BACKGROUND: MATERIAL AND METHODS: Twenty prepubertal children with idiopathic epilepsy treated with VPA were enrolled in this study. Body mass index (BMI) and fasting insulin glucose ratio (FIGR) were calculated, and the plasma insulin, leptin, NPY, ghrelin, and adiponectin levels; the lipid profiles; and CAIMT were measured for all subjects before the treatment and after a follow-up period of 6 and 12 months. RESULTS: When pretreatment values were compared with those at the end of 6 and 12 months, the mean BMI values, plasma insulin, leptin, NPY levels, and FIGR were increased, whereas the plasma ghrelin and adiponectin levels, lipid profiles, and CAIMT did not change significantly at the end of 6 and 12 months. CONCLUSION: These results suggest that weight gain during VPA treatment may be related to increases in insulin, leptin, and NPY levels. Additionally, in this study, no increase in the risk for early atherosclerosis was determined by CAIMT in children with epilepsy treated with VPA.
|
Authors | Huseyin Tokgoz, Kursad Aydin, Bulent Oran, Aysel Kiyici |
Journal | Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
(Childs Nerv Syst)
Vol. 28
Issue 7
Pg. 1049-53
(Jul 2012)
ISSN: 1433-0350 [Electronic] Germany |
PMID | 22645062
(Publication Type: Journal Article)
|
Chemical References |
- Adiponectin
- Anticonvulsants
- Blood Glucose
- Ghrelin
- Insulin
- Leptin
- Neuropeptide Y
- Valproic Acid
|
Topics |
- Adiponectin
(blood)
- Age Factors
- Anticonvulsants
(adverse effects)
- Blood Glucose
(drug effects)
- Body Mass Index
- Carotid Intima-Media Thickness
- Child
- Epilepsy
(blood, drug therapy)
- Female
- Follow-Up Studies
- Ghrelin
(blood)
- Humans
- Insulin
(blood)
- Leptin
(blood)
- Male
- Neuropeptide Y
(blood)
- Valproic Acid
(adverse effects)
|